CD19 and precursor B-cell acute lymphoblastic leukemia: In this context, a TriKE containing anti-CD19 and anti-CD22 has been designed [195] to overcome the possible appearance of CD19− leukemic blasts that was observed upon blinatumomab treatment in around 20% of pediatric B-ALL patients given the drug [201] (Figure 2).